<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03802604</url>
  </required_header>
  <id_info>
    <org_study_id>SOLTI-1503</org_study_id>
    <secondary_id>2018-001300-10</secondary_id>
    <nct_id>NCT03802604</nct_id>
  </id_info>
  <brief_title>Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer</brief_title>
  <acronym>PROMETEO</acronym>
  <official_title>Combination of Talimogene Laherparepvec With Atezolizumab in Patients With Residual Breast Cancer After Standard Neoadjuvant Multi-agent Chemotherapy (PROMETEO TRIAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SOLTI Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SOLTI Breast Cancer Research Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PROMETEO is a window opportunity, single arm, exploratory study to evaluate the effect of T-&#xD;
      VEC combined with Atezolizumab in women with operable early breast cancer who present&#xD;
      residual disease after Neoadjuvant Chemotherapy (NAC). Other eligibility criteria include&#xD;
      TNBC or LumB like primary tumor sized at least 1.5 cm, ECOG PS 0-1 and evaluable diagnostic&#xD;
      tumor sample.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective:&#xD;
&#xD;
      • To evaluate the efficacy (as measured by residual cancer burden [RCB] class 0/1 rate) of&#xD;
      Talimogene Laherparepvec with Atezolizumab given to subjects with operable early breast&#xD;
      cancer who present residual disease after neoadjuvant chemotherapy (NAC).&#xD;
&#xD;
      Secondary objectives include:&#xD;
&#xD;
        -  To assess the rate of pathological complete response (pCR) in the breast (pCRB) and&#xD;
           breast and axilla (pCRBL) at definitive surgery after neoadjuvant treatment with T-VEC&#xD;
           and atezolizumab.&#xD;
&#xD;
        -  To determine the clinical and radiological ORR of breast tumors to TVEC- atezolizumab&#xD;
           given in the neoadjuvant setting.&#xD;
&#xD;
        -  To assess RCB index in continuous variable and by the 4 RCB class (RCB0, RCB1, RCB2 and&#xD;
           RCB 3) after treatment with T-VEC and atezolizumab.&#xD;
&#xD;
        -  Comparing the expression of a gene signature tracking activated CD8 T-cells at surgery&#xD;
           after treatment with T-VEC and atezolizumab with residual disease after NAC.&#xD;
&#xD;
        -  To evaluate the safety of T-VEC in combination with atezolizumab as assessed by&#xD;
           incidence of treatment-emergent and treatment-related adverse events.&#xD;
&#xD;
        -  Translational and exploratory objectives are included.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 10, 2018</start_date>
  <completion_date type="Anticipated">April 27, 2025</completion_date>
  <primary_completion_date type="Actual">April 27, 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of residual cancer burden class 0 and 1 (RCB0/1)</measure>
    <time_frame>24 months since first patient in</time_frame>
    <description>As a dichotomous measure of tumor response, RCB 0/1 yes vs. no., after neoadjuvant treatment, according to the MD Anderson Cancer Center procedures, as per local assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of pCRB (ypT0/Tis) and pCRBL (ypT0/TisypN0)</measure>
    <time_frame>24 months since first patient in</time_frame>
    <description>Complete absence of invasive carcinoma in the breast or in the breast and axillary lymph nodes on histological examination at the time of definitive surgery, irrespective of in situ carcinoma in the breast and in the breast and axilla by local evaluation will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor ORR</measure>
    <time_frame>24 months since first patient in</time_frame>
    <description>Defined as the sum of PR and CR according to RECIST v1.1, as per Investigator's assessments by breast MRI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of residual cancer burden (RCB)</measure>
    <time_frame>24 months since first patient in</time_frame>
    <description>As a continuous variable and by RCB group, after neoadjuvant treatment, according to the MD Anderson Cancer Center procedures, as per local assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the expression of a gene signature tracking activated CD8 T-cells.</measure>
    <time_frame>24 months since first patient in</time_frame>
    <description>Differences in in the mean expression of an immune gene signature tracking CD8 T-cells (composed of the following genes: PRF1, CD8A, GZMM, CD8B, FLT3LG) in all patients will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence, duration and severity of AEs assessed by the NCI Common Terminology for Classification of Adverse Events (CTCAE) version 4</measure>
    <time_frame>24 months since first patient in</time_frame>
    <description>Incidence, duration and severity of AEs assessed by the NCI Common Terminology for Classification of Adverse Events (CTCAE) version 4, including delays and treatment discontinuations.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Talimogene laherparepvec + Atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Talimogene laherparepvec: Cycle 1 - 10^6 PFU/mL. Cycle 2, 3, 4 &amp; 5 - 10^8 PFU/mL.&#xD;
Atezolizumab 840 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Talimogene laherparepvec</intervention_name>
    <description>Talimogene laherparepvec will be given via intra-tumoral injection at an initial dose of 10^6 PFU/mL. On week 3 (i.e. 21 days [± 2] days), a second talimogene laherparepvec injection will be administered at a dose of 10^8 PFU/mL. Third, fourth and fifth injections will be administered every 2 weeks (every 14 [± 2] days). The maximum volume for each injection will be 4.0 mL.</description>
    <arm_group_label>Talimogene laherparepvec + Atezolizumab</arm_group_label>
    <other_name>T-VEC</other_name>
    <other_name>Imlygic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>Atezolizumab 840 mg will be administered by IV infusion on Day1 week 3, then every 2 weeks (every 14 [± 2] days), for a total of 4 treatment courses.</description>
    <arm_group_label>Talimogene laherparepvec + Atezolizumab</arm_group_label>
    <other_name>Tecentric</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patient inclusion criteria&#xD;
&#xD;
          1. Written informed consent for all study procedures according to local regulatory&#xD;
             requirements prior to beginning specific protocol procedures.&#xD;
&#xD;
          2. Female patients age ≥18 years at the time of informed consent.&#xD;
&#xD;
          3. Histologically confirmed diagnosis of non-metastatic primary invasive adenocarcinoma&#xD;
             of the breast, with all of the following characteristics:&#xD;
&#xD;
               -  TNBC or luminal B-like/HER2-negative breast cancer.&#xD;
&#xD;
               -  At least 1 lesion that can be accurately and serially measured in at least 1&#xD;
                  dimension and for which the longest diameter is ≥ 10 mm as measured by magnetic&#xD;
                  resonance imaging (MRI).&#xD;
&#xD;
               -  Breast cancer eligible for primary surgery&#xD;
&#xD;
               -  In the case of a multifocal/multicentric tumor, the largest lesion must be ≥ 15&#xD;
                  mm and designated the &quot;target&quot; lesion for all subsequent tumor evaluations.&#xD;
&#xD;
          4. ER, PgR and HER2 tumor determination by ASCO/CAP guidelines locally assessed:&#xD;
&#xD;
               -  TNBC defined as: ER and PR negative defined as IHC nuclear staining &lt;1% AND HER2&#xD;
                  negative.&#xD;
&#xD;
               -  Luminal B-like/HER2 negative defined as:&#xD;
&#xD;
                    -  ER or PR positive defined as IHC nuclear staining ≥1% AND HER2 negative AND&#xD;
                       local Ki-67 ≥20% or&#xD;
&#xD;
          5. Patient must have injectable and biopsiable disease (direct injection or ultrasound&#xD;
             guided).&#xD;
&#xD;
          6. Completed ≥ 80% total dose of an anthracycline/taxane-based neoadjuvant regimen&#xD;
             recommended by the NCCN guidelines. The addition of carboplatin to a taxane is&#xD;
             allowed.&#xD;
&#xD;
          7. ECOG Performance Status of 0 or 1.&#xD;
&#xD;
          8. Adequate organ function determined within 14 days prior to enrollment, defined as&#xD;
             follows:&#xD;
&#xD;
               -  Hematological&#xD;
&#xD;
                    -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L&#xD;
&#xD;
                    -  Platelet count ≥ 100 x 109/L&#xD;
&#xD;
                    -  Hemoglobin ≥ 9 g/dL (red blood cell transfusion and/or erythropoietin&#xD;
                       allowed)&#xD;
&#xD;
               -  Renal&#xD;
&#xD;
                  o Serum creatinine ≤ 1.5 x upper limit of normal (ULN), or 24-hour creatinine&#xD;
                  clearance ≥ 60 mL/min for subject with creatinine levels &gt; 1.5 x ULN. (Note:&#xD;
                  Creatinine clearance does not need to be determined if the baseline serum&#xD;
                  creatinine is within normal limits. Creatinine clearance should be calculated per&#xD;
                  institutional standard).&#xD;
&#xD;
               -  Hepatic&#xD;
&#xD;
                    -  serum bilirubin ≤ 1.5 x ULN OR direct bilirubin ≤ ULN for a subject with&#xD;
                       total bilirubin level &gt; 1.5 x ULN&#xD;
&#xD;
                    -  aspartate aminotransferase (AST) ≤ 2.5 x ULN alanine aminotransferase (ALT)&#xD;
                       ≤ 2.5 x ULN&#xD;
&#xD;
                    -  Coagulation International normalization ratio (INR) or prothrombin time (PT)&#xD;
                       ≤ 1.5 x ULN&#xD;
&#xD;
          9. Partial thromboplastin time (PTT) or activated PTT (aPTT) ≤ 1.5 x ULN&#xD;
&#xD;
         10. Absence of any psychological, familial, sociological or geographical situation&#xD;
             potentially hampering compliance with the study protocol and follow-up schedule; those&#xD;
             situations should be discussed with the patient before registration in the trial.&#xD;
&#xD;
         11. Female subject of childbearing potential should have a negative urine or serum&#xD;
             pregnancy test within 72 hours prior to enrollment. If urine pregnancy test is&#xD;
             positive or cannot be confirmed as negative, a serum pregnancy test will be required.&#xD;
&#xD;
         12. Resolution of all acute toxic effects of prior anti-cancer therapy or surgical&#xD;
             procedures to NCI CTCAE version 4.0 Grade ≤ 1 (except alopecia or other toxicities not&#xD;
             considered a safety risk for the patient at investigator´s discretion).&#xD;
&#xD;
        Patient exclusion criteria&#xD;
&#xD;
          1. Inoperable locally advanced breast cancer after NAC.&#xD;
&#xD;
          2. Metastatic (Stage IV) breast cancer.&#xD;
&#xD;
          3. Bilateral invasive breast cancer.&#xD;
&#xD;
          4. Prior therapy with an anti- PD-1, anti- PD-L1, anti-PD-L2, anti-CD137 antibody, or&#xD;
             anti-CTLA- 4 antibody compound, T-VEC or any other oncolytic immunotherapy.&#xD;
&#xD;
          5. Prior therapy with tumor vaccine.&#xD;
&#xD;
          6. Currently receiving treatment in another investigational device or study drug, or less&#xD;
             than 28 days since ending treatment on another investigational device or study drug.&#xD;
&#xD;
          7. History or evidence of symptomatic autoimmune pneumonitis, glomerulonephritis,&#xD;
             vasculitis, or other symptomatic autoimmune disease, or active autoimmune disease or&#xD;
             syndrome that has required systemic treatment in the past 2 years (ie, with use of&#xD;
             disease modifying agents, corticosteroids or immunosuppressive drugs). with the&#xD;
             following exceptions:&#xD;
&#xD;
               -  Patients with a history of autoimmune-related hypothyroidism who are on thyroid&#xD;
                  replacement hormone are eligible for the study.&#xD;
&#xD;
               -  Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen&#xD;
                  are eligible for the study.&#xD;
&#xD;
               -  Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with&#xD;
                  dermatologic manifestations only (e.g., patients with psoriatic arthritis are&#xD;
                  excluded) are eligible for the study provided all of following conditions are&#xD;
                  met:&#xD;
&#xD;
             Rash must cover 10% of body surface. Disease is well controlled at baseline and&#xD;
             requires only low-potency topical corticosteroids.&#xD;
&#xD;
             No occurrence of acute exacerbations of the underlying condition requiring psoralen&#xD;
             plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral&#xD;
             calcineurin inhibitors, or high potency or oral corticosteroids within the previous 12&#xD;
             months.&#xD;
&#xD;
          8. Active herpetic skin lesions or prior complications of herpetic infection (e.g.&#xD;
             herpetic keratitis or encephalitis) and must not require intermittent or chronic&#xD;
             treatment with an antiherpetic drug (e.g. acyclovir), other than intermittent topical&#xD;
             use.&#xD;
&#xD;
          9. Received live vaccine within 28 days prior to enrollment or within 5 months after the&#xD;
             last dose of atezolizumab.&#xD;
&#xD;
         10. Evidence of clinically significant immunosuppression such as the following:&#xD;
&#xD;
               -  diagnosis of immunodeficiency&#xD;
&#xD;
               -  concurrent opportunistic infection&#xD;
&#xD;
               -  receiving systemic immunosuppressive therapy (&gt; 2 weeks) or within 7 days prior&#xD;
                  to the first dose of study treatment, including oral steroid doses &gt; 10 mg/day of&#xD;
                  prednisone or equivalent. Subjects that require intermittent use of&#xD;
                  bronchodilators or local steroid injection will not be excluded from the study.&#xD;
&#xD;
         11. Cardiopulmonary dysfunction as defined by:&#xD;
&#xD;
               -  Uncontrolled hypertension (systolic &gt;150 mm Hg and/or diastolic &gt; 100 mm Hg)&#xD;
                  despite optimal medical management.&#xD;
&#xD;
               -  Inadequately controlled angina or serious cardiac arrhythmia not controlled by&#xD;
                  adequate medication.&#xD;
&#xD;
               -  History of symptomatic congestive heart failure (CHF): Grade ≥ 3 per NCI CTCAE&#xD;
                  version 4.0 or Class ≥ II New York Health Association (NYHA criteria).&#xD;
&#xD;
               -  Myocardial infarction within 6 months prior to enrollment.&#xD;
&#xD;
               -  Current dyspnea at rest due to complications of advanced malignancy, or other&#xD;
                  disease requiring continuous oxygen therapy&#xD;
&#xD;
         12. Current severe, uncontrolled systemic disease (e.g. clinically significant&#xD;
             cardiovascular, pulmonary or metabolic disease; wound healing disorders; ulcers; bone&#xD;
             fractures).&#xD;
&#xD;
         13. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent&#xD;
             drainage procedures (once monthly or more frequently). Patients with indwelling&#xD;
             catheters (e.g., PleurX) are allowed.&#xD;
&#xD;
         14. Uncontrolled or symptomatic hypercalcemia (ionized calcium 1.5 mmol/L, calcium 12&#xD;
             mg/dL or corrected serum calcium ULN)&#xD;
&#xD;
         15. History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis&#xD;
             obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of&#xD;
             active pneumonitis on screening chest computed tomography (CT) scan. History of&#xD;
             radiation pneumonitis in the radiation field (fibrosis) is permitted.&#xD;
&#xD;
         16. Major surgical procedure or significant traumatic injury within approximately 28 days&#xD;
             prior to enrollment or anticipation of the need for major surgery during the course of&#xD;
             study treatment.&#xD;
&#xD;
         17. Concurrent, serious, uncontrolled infections or current known infection with HIV or&#xD;
             active hepatitis B and/or hepatitis C.&#xD;
&#xD;
         18. Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation&#xD;
             of study treatment with exception of prophylactic antibiotics&#xD;
&#xD;
         19. Has a known history of active Bacillus tuberculosis&#xD;
&#xD;
         20. Female subject is pregnant or breast-feeding, or planning to become pregnant during&#xD;
             study treatment and through 3 months after the last dose of talimogene laherparepvec&#xD;
             or 5 months after the last dose of atezolizumab, whichever is later&#xD;
&#xD;
         21. Female subject of childbearing potential who is unwilling to use acceptable method(s)&#xD;
             of effective contraception during study treatment and through 3 months after the last&#xD;
             dose of talimogene laherparepvec or 5 months after the last dose of atezolizumab,&#xD;
             whichever is later. Note: Women not of childbearing potential are defined as:&#xD;
&#xD;
               -  postmenopausal (defined as at least 12 months with no menses without an&#xD;
                  alternative medical cause; in women &lt; 45 years of age a high follicle stimulating&#xD;
                  hormone (FSH) level in the postmenopausal range may be used to confirm a&#xD;
                  post-menopausal state in women not using hormonal contraception or hormonal&#xD;
                  replacement therapy. In the absence of 12 months of amenorrhea, a single FSH&#xD;
                  measurement is insufficient.) OR&#xD;
&#xD;
               -  have had a hysterectomy and/or bilateral oophorectomy, bilateral salpingectomy or&#xD;
                  bilateral tubal ligation/occlusion, at least 6 weeks prior to screening; OR&#xD;
&#xD;
               -  has a congenital or acquired condition that prevents childbearing.&#xD;
&#xD;
             Note: Acceptable methods of effective contraception are defined in the informed&#xD;
             consent form and Appendix A.&#xD;
&#xD;
         22. Subject has known sensitivity to any of the products or components to be administered&#xD;
             during dosing&#xD;
&#xD;
         23. Assessment by the investigator to be unable or unwilling to comply with the&#xD;
             requirements of the protocol.&#xD;
&#xD;
         24. History of other malignancy within 5 years prior to screening, except for&#xD;
             appropriately treated basal or squamous cell carcinoma, carcinoma in situ of the&#xD;
             cervix, non-melanoma skin carcinoma, or Stage I uterine cancer.&#xD;
&#xD;
         25. History of significant co-morbidities that, in the judgment of the investigator, may&#xD;
             interfere with the conduction of the study, the evaluation of response, or with&#xD;
             informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aleix Prat</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebrón</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Integral Oncológico Clara Campal</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2023</verification_date>
  <study_first_submitted>November 15, 2018</study_first_submitted>
  <study_first_submitted_qc>January 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2019</study_first_posted>
  <last_update_submitted>June 21, 2023</last_update_submitted>
  <last_update_submitted_qc>June 21, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atezolizumab</keyword>
  <keyword>T-vec</keyword>
  <keyword>talimogene laherparepvec</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Talimogene laherparepvec</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03802604
org study id: SOLTI-1503
secondary id: 2018-001300-10
nct id: NCT03802604
lead sponsor: 
collaborator: 
collaborator: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
PROMETEO is a window opportunity, single arm, exploratory study to evaluate the effect of T-
      VEC combined with Atezolizumab in women with operable early breast cancer who present
      residual disease after Neoadjuvant Chemotherapy (NAC). Other eligibility criteria include
      TNBC or LumB like primary tumor sized at least 1.5 cm, ECOG PS 0-1 and evaluable diagnostic
      tumor sample.
Primary objective:

      • To evaluate the efficacy (as measured by residual cancer burden [RCB] class 0/1 rate) of
      Talimogene Laherparepvec with Atezolizumab given to subjects with operable early breast
      cancer who present residual disease after neoadjuvant chemotherapy (NAC).

      Secondary objectives include:

        -  To assess the rate of pathological complete response (pCR) in the breast (pCRB) and
           breast and axilla (pCRBL) at definitive surgery after neoadjuvant treatment with T-VEC
           and atezolizumab.

        -  To determine the clinical and radiological ORR of breast tumors to TVEC- atezolizumab
           given in the neoadjuvant setting.

        -  To assess RCB index in continuous variable and by the 4 RCB class (RCB0, RCB1, RCB2 and
           RCB 3) after treatment with T-VEC and atezolizumab.

        -  Comparing the expression of a gene signature tracking activated CD8 T-cells at surgery
           after treatment with T-VEC and atezolizumab with residual disease after NAC.

        -  To evaluate the safety of T-VEC in combination with atezolizumab as assessed by
           incidence of treatment-emergent and treatment-related adverse events.

        -  Translational and exploratory objectives are included.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Rate of residual cancer burden class 0 and 1 (RCB0/1)
time frame: 24 months since first patient in
description: As a dichotomous measure of tumor response, RCB 0/1 yes vs. no., after neoadjuvant treatment, according to the MD Anderson Cancer Center procedures, as per local assessment.
measure: Rate of pCRB (ypT0/Tis) and pCRBL (ypT0/TisypN0)
time frame: 24 months since first patient in
description: Complete absence of invasive carcinoma in the breast or in the breast and axillary lymph nodes on histological examination at the time of definitive surgery, irrespective of in situ carcinoma in the breast and in the breast and axilla by local evaluation will be assessed.
measure: Tumor ORR
time frame: 24 months since first patient in
description: Defined as the sum of PR and CR according to RECIST v1.1, as per Investigator's assessments by breast MRI.
measure: Rate of residual cancer burden (RCB)
time frame: 24 months since first patient in
description: As a continuous variable and by RCB group, after neoadjuvant treatment, according to the MD Anderson Cancer Center procedures, as per local assessment.
measure: Changes in the expression of a gene signature tracking activated CD8 T-cells.
time frame: 24 months since first patient in
description: Differences in in the mean expression of an immune gene signature tracking CD8 T-cells (composed of the following genes: PRF1, CD8A, GZMM, CD8B, FLT3LG) in all patients will be assessed.
measure: Incidence, duration and severity of AEs assessed by the NCI Common Terminology for Classification of Adverse Events (CTCAE) version 4
time frame: 24 months since first patient in
description: Incidence, duration and severity of AEs assessed by the NCI Common Terminology for Classification of Adverse Events (CTCAE) version 4, including delays and treatment discontinuations.
arm group label: Talimogene laherparepvec + Atezolizumab
arm group type: Experimental
description: Talimogene laherparepvec: Cycle 1 - 10^6 PFU/mL. Cycle 2, 3, 4 & 5 - 10^8 PFU/mL.
Atezolizumab 840 mg
intervention type: Biological
intervention name: Talimogene laherparepvec
description: Talimogene laherparepvec will be given via intra-tumoral injection at an initial dose of 10^6 PFU/mL. On week 3 (i.e. 21 days [± 2] days), a second talimogene laherparepvec injection will be administered at a dose of 10^8 PFU/mL. Third, fourth and fifth injections will be administered every 2 weeks (every 14 [± 2] days). The maximum volume for each injection will be 4.0 mL.
arm group label: Talimogene laherparepvec + Atezolizumab
other name: T-VEC
other name: Imlygic
intervention type: Drug
intervention name: Atezolizumab
description: Atezolizumab 840 mg will be administered by IV infusion on Day1 week 3, then every 2 weeks (every 14 [± 2] days), for a total of 4 treatment courses.
arm group label: Talimogene laherparepvec + Atezolizumab
other name: Tecentric
criteria: 
gender: Female
minimum age: 18 Years
maximum age: 99 Years
healthy volunteers: No
last name: Aleix Prat
role: Principal Investigator
affiliation: Hospital Clinic of Barcelona
facility: 
facility: 
facility: 
facility: 
country: Spain
responsible party type: Sponsor
mesh term: Breast Neoplasms
mesh term: Atezolizumab
mesh term: Talimogene laherparepvec
sharing ipd: No